Loading...
Loading...
VTGN| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.1M |
| Operating Expense | 12.2M |
| Operating I/L | -12.1M |
| Other Income/Expense | 1.4M |
| Interest Income | 1.4M |
| Pretax | -10.7M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -10.7M |
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing medicines for anxiety, depression, and other CNS disorders. Their CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray in Phase III development for treating anxiety in adults with social anxiety disorder. Additionally, they are preparing PH10, a neuroactive nasal spray, for Phase 2B clinical development as a stand-alone treatment for major depressive disorder. They also have AV-101, an oral N-methyl-D-aspartate receptor antagonist, in development for various conditions. The company generates revenue through the development and potential commercialization of these CNS therapies.
